Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Capital Expenditures: 2020-2024

Historic Capital Expenditures for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to $3.8 million.

  • Oncology Institute's Capital Expenditures rose 25024.88% to $604000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 665.66%. This contributed to the annual value of $3.8 million for FY2024, which is 1703.53% down from last year.
  • Oncology Institute's Capital Expenditures amounted to $3.8 million in FY2024, which was down 1703.53% from $4.6 million recorded in FY2023.
  • Oncology Institute's Capital Expenditures' 5-year high stood at $5.5 million during FY2022, with a 5-year trough of $1.2 million in FY2020.
  • Moreover, its 5-year median value for Capital Expenditures was $3.8 million (2024), whereas its average is $3.6 million.
  • Per our database at Business Quant, Oncology Institute's Capital Expenditures skyrocketed by 13844.22% in 2021 and then crashed by 1739.92% in 2023.
  • Annual analysis of 5 years shows Oncology Institute's Capital Expenditures stood at $1.2 million in 2020, then surged by 138.44% to $2.8 million in 2021, then surged by 94.2% to $5.5 million in 2022, then decreased by 17.4% to $4.6 million in 2023, then decreased by 17.04% to $3.8 million in 2024.
  • Its last three reported values are $3.8 million in FY2024, $4.6 million for FY2023, and $5.5 million during FY2022.